OTC stock swing trader
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MC only $466k, a very undervalued stock with $57m coming in.
Going up is confirmed
News out
HIMALAYA TECHNOLOGIES TO ENTER CRYTPOCURRENCY MARKET
1d
0.00%
+50.00%
Pittsburgh, PA, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Himalaya Technologies, Inc. (OTC: HMLA) announces it intends to enter the cryptocurrency market through an investment agreement with its CEO Vikram Grover, who recently received a substantial default judgment against an operator of a crypto tech ecosystem including cryptocurrency exchanges, crypto coins and tokens, and value added blockchain products and services. Specifically, on December 20, 2023, Vikram Grover was notified that he won a default judgment of $57,903,750.00 not including damages and legal fees for Case No.: 1:21-cv-05054 in the United States District Court for the Northern District of Illinois Eastern Division. The complaint, filed on or around September 3, 2021, is Vikram Grover v. Net Savings Link, Inc., Wilton Group, Limited, Wilton UK (Group), LTD, Wilton Group, Limited, China Food and Beverage Co., and James Tilton.
Mr. Grover, who is our control shareholder, has agreed to enforce the judgment and seek control of the defendants’ public companies Net Savings Link, Inc. and China Food and Beverage Co. (both publicly traded on OTC Markets), obtain their crypto businesses, fintech investments and other assets, and combine them with Himalaya. Any transactions will be subject to independent valuation and analysis and compliance with US GAAP, regulatory rules, and legal requirements.
Said Vik Grover, CEO: “The default judgment, which I was notified of last week, is the culmination of a business dispute from several years ago that drove me to file legal action in federal court in 2021. Now entering the collection and enforcement stage of this process, I believe the business assets at Net Savings Link, Inc. and China Food and Beverage Co., have significant upside within the framework of a properly capitalized, fully reporting audited public company such as Himalaya that can raise institutional capital. Comparing the Net Savings Link, Inc. and China Food and Beverage Co., current market capitalizations to HMLA’s much smaller valuation reveals an obvious and substantial valuation gap, but when HMLA’s market value is compared to the peak valuations of these defendants of several hundred million dollars, the valuation gap is extraordinary and possibly game changing. With Himalaya’s audited, clean public platform, we are poised to capitalize the business properly, infuse these businesses and assets into our holding company, and create lasting value for our stakeholders and affiliates in the New Year.”
Summary of Investments and Assets of Net Savings Link, Inc.:
https://www.otcmarkets.com/otcapi/company/financial-report/388998/content
Disclaimer
There are currently no merger agreements, plans of merger, or investment agreements signed between Himalaya Technologies, Inc. and any of these potential target transactions. Both Vikram Grover and Himalaya have signed a memorandum of understanding (“MOU”) to explore the infusion of these businesses, investments and assets into the Company pending collection efforts. There are no assurances that Himalaya will successfully finance any business or close any of the aforementioned potential strategic transactions. Further information on the legal case, judgment, and MOU are available on the SEC’s EDGAR system under Form 8-K filed December 26, 2023 at https://www.sec.gov/edgar/searchedgar/companysearch under "Himalaya Technologies, Inc." and/or "HMLA".
About Himalaya Technologies, Inc.
Himalaya Technologies, Inc. (https://www.himalayatechnologies.com) is a publicly traded entity (OTC: HMLA) focusing on minority and majority investments in businesses seeking access to growth capital to fulfill their own business plans and create value for their stakeholders and the Company’s debt and equity investors. The Company is a minority investment of FOMO WORLDWIDE, INC. (OTC: FOMC; https://www.fomoworldwide.com).
In at 20, looks going up, big rebound coming.
MaRKET CAP ONLY $500K, with $5mm revenue, VERY UNDERVALUED STOCK, ready to move up
Share Structure
Market Cap Market Cap
540,587
12/27/2023
Authorized Shares
5,000,000,000
12/25/2023
Outstanding Shares
360,391,317
12/25/2023
Restricted
135,040,810
12/25/2023
Unrestricted
225,350,507
12/25/2023
Held at DTC
223,466,956
12/25/2023
Float
15,747,507
06/30/2023
Par Value
0.001
Tomorrow lets go break out 0.003
Looks like RDGL will be beak out 0.08 Tomorrow.
I don't think I can get 0.0009 again,If I can get 0.0015 area I will feel luck,
smells another good news will be out any time very soon, Are we ready?
Ready to break out 0.08 today, day trading reversed to north now.
OTC stocks, after one day big up, usually need two days pull back. Tomorrow we will see pull back continue.
This stock from 0.0009 to 0.0033 and from 0.001 to 0.0033 in one day, two time run fast like this. Today can we see 0.003 again???!!!
BCNN is a very undervalued stock, MC only $360k with $5m revenue.???????????????????
Share Structure
Market Cap Market Cap
360,391
12/26/2023
Authorized Shares
5,000,000,000
12/25/2023
Outstanding Shares
360,391,317
12/25/2023
Restricted
135,040,810
12/25/2023
Unrestricted
225,350,507
12/25/2023
Held at DTC
223,466,956
12/25/2023
Float
15,747,507
06/30/2023
Par Value
0.001
Lets break out 0.003 Tomorrow if not today. This stock run fast as before.
BCNN trend is reversed from today. go north direction
Charts looks we will break out 0.08 today, uptrend continue until big gap up coming one day. with IDE news
See tomorrow pull back
In your experience, Tomorrow it will pull back?
I sold HMLA at 0.0009 to buy this stock, but today HMLA increasing 200% with law suit win $57m,terrible for me.
Only 40k shares left for sell below 0.08. Go break out 0.08 today.
This stock trading like no revenue company.
I sold out at 9 with one tick profits,but missed big profit.
thanks
I missed a chance
news leaked?
Tomorrow huge buyers will come in to buy RDGL, PPS will break out 0.10 any day before Friday. Every one got Christmas gift
Next Monday will be interesting after people readed news. More buyers will come in to buy RDGL shares, PPS will rock
RDGL has bright future, IDE will be approved for sure, not yes or no, just when, soon or sooner, see break out 0.10 next week.at least.
Only things is that people are scared by 5b A/S, a lot of company with 5B shares trading much higher than this company without revenue. This undervalued stock will fly soon and become a winner in 2024.
BCNN is a very undervalued stock, and is a #1 oever sold stock, it should trade at pennies at least now. MMs should correct their mistake.
If IDE approved, the PPS will gap up to $1, not surprised
Stupid sellars sold at low yesterday, now they must buy high. This stock will gap up big any time soon
IDE submit will be very very soon:
With the Breakthrough Device classification, Vivos Inc. is set to expedite its Investigational Device Exemption (IDE) submission to the FDA, paving the way for human clinical trials. This collaboration with the Mayo Clinic for its initial indication marks a significant step forward in the fight against challenging cancer types, offering hope and potentially more effective treatment options to patients globally.
Excellent comments:
RDGL News
New Hope In Cancer Battle: FDA Grants Breakthrough Device Status To Vivos Inc.'s RadioGel
20h
0.00%
11:58 AM EST, December 21, 2023 (Benzinga Newswire)
In a significant advancement for cancer therapy, the Food and Drug Administration (FDA) has awarded RadioGel Precision Radionuclide Therapy the coveted Breakthrough Device Designation. Developed by Vivos Inc. (OTCQB:RDGL), this designation marks a crucial milestone in the treatment of solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer.
How RadioGel Works
RadioGel, a pioneering Yttrium-90-based injectable brachytherapy device, represents a groundbreaking approach to cancer treatment. It is designed for patients who are either not eligible for surgery or have chosen not to undergo the procedure, particularly those with non-radioiodine avid disease and limited burden regional nodal disease.
The therapy involves directly injecting a hydrogel containing yttrium-90 phosphate microparticles into the tumor. This method allows for a more localized and potent radiation treatment compared to traditional external-beam radiation therapies.
Dr. Mike Korenko, CEO of Vivos Inc., expressed his satisfaction with the FDA's decision, citing the thorough review process and the positive results from their Risk Management Report and animal therapy data. "The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel is intrinsically safe and our animal therapy data verified its effectiveness," Korenko said.
Also Read: Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Pharma Stocks Too?
What's The FDA's Breakthrough Devices Program
The Breakthrough Devices Program by the FDA is designed to accelerate the development and review of innovative technologies that show potential for more effective treatment options. The program's support is instrumental in hastening patient access to promising medical advancements.
RadioGel's hydrogel technology allows for the safe delivery of higher doses necessary for treating non-resectable and radiation-resistant cancers. The product also boasts a short half-life, delivering over 90% of its therapeutic radiation within 10 days.
This feature compares favorably to other treatments that require up to six weeks for a full course of radiation therapy. Additionally, the outpatient nature of the RadioGel therapy means patients can return home without concerns about radiation exposure to family members.
With the Breakthrough Device classification, Vivos Inc. is set to expedite its Investigational Device Exemption (IDE) submission to the FDA, paving the way for human clinical trials. This collaboration with the Mayo Clinic for its initial indication marks a significant step forward in the fight against challenging cancer types, offering hope and potentially more effective treatment options to patients globally.
Now Read: Cannabis Commonly Used As Sleep Aid By Cancer Survivors, New Research Finds
Photo by National Cancer Institute on Unsplash
Write to Benzinga at editorial@benzinga.com
Looks like big rebound by Tomorrow.
Over pull back is over. this stock should go up to green today.
I love your $8 target for buy out.
Little pull back, then go up continue, let's break out 0.10 today
Tomorrow PDPG will move up lets see.
ETEK is R/m winner in 2024,hold on your shares